Sex differences in type 2 diabetes: focus on disease course and outcomes

QR Code

Sex differences in type 2 diabetes: focus on disease course and outcomes

Lisa Arnetz,1,2 Neda Rajamand Ekberg,1,2 Michael Alvarsson1,2 1Department of Molecular Medicine and Surgery, Karolinska Institutet, 2Department of Endocrinology, Metabolism and Diabetes, Stockholm, Sweden Background: Women with type 2 diabetes (T2D) are less likely to reach the goals for hemoglobi...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Arnetz L, Ekberg NR, Alvarsson M
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2014
Sujets:	Specialties of internal medicine RC581-951
Accès en ligne:	https://doaj.org/article/fdd2dd7c0ce64d25b5d0457bd398e3f8
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes
par: Gallwitz B
Publié: (2013)

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
par: Bo Ahr&eacute;n
Publié: (2010)

Management of diabetes across the course of disease: minimizing obesity-associated complications
par: Apovian CM
Publié: (2011)

Sexual dysfunction in diabetic women: prevalence and differences in type 1 and type 2 diabetes mellitus
par: Mazzilli R, et autres
Publié: (2015)

SGLT2 inhibitors – an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin
par: Seufert J
Publié: (2015)

Glucagon-like peptide-1 receptor agonists as add-on therapy to basal insulin in patients with type 2 diabetes: a systematic review
par: Berlie H, et autres
Publié: (2012)

Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus
par: Lorber D
Publié: (2014)

Using the health action process approach to predict and improve health outcomes in individuals with type 2 diabetes mellitus
par: MacPhail M, et autres
Publié: (2014)

Treatment of type 2 diabetes in chronic kidney disease: a case for linagliptin in the treatment of diabetes in severe renal impairment
par: Scott D
Publié: (2013)

Saxagliptin for type 2 diabetes
par: Antonio R Chacra, et autres
Publié: (2010)

Role of implants in the treatment of diabetic macular edema: focus on the dexamethasone intravitreal implant
par: Cebeci Z, et autres
Publié: (2015)

Variability in Zucker diabetic fatty rats: differences in disease progression in hyperglycemic and normoglycemic animals
par: Wang X, et autres
Publié: (2014)

Type 2 diabetes in Brazil: epidemiology and management
par: Almeida-Pititto B, et autres
Publié: (2015)

Partnering with diabetes educators to improve patient outcomes
par: Burke SD, et autres
Publié: (2014)

Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin
par: Russo E, et autres
Publié: (2013)

Linking obesity with type 2 diabetes: the role of T-bet
par: Wali JA, et autres
Publié: (2014)

Comparative effectiveness of liraglutide in the treatment of type 2 diabetes
par: Rigato M, et autres
Publié: (2014)

Risk management in the treatment of type 2 diabetes with pioglitazone
par: Giuseppe Derosa, et autres
Publié: (2009)

Analog insulin detemir for patients with type 1 and type 2 diabetes: a review
par: Gregory E Peterson
Publié: (2009)

Outcomes of Roux-en-Y gastric bypass surgery for severely obese patients with type 1 diabetes: a case series report
par: Carlos E Mendez, et autres
Publié: (2010)

Evidence for the benefit of exercise therapy in patients with type 2 diabetes
par: Madden KM
Publié: (2013)

Insulin detemir for the treatment of obese patients with type 2 diabetes
par: Hollander PA
Publié: (2012)

AMPK activation: a therapeutic target for type 2 diabetes?
par: Coughlan KA, et autres
Publié: (2014)

Sitagliptin as combination therapy in the treatment of type 2 diabetes mellitus
par: Shannon A Miller, et autres
Publié: (2009)

Red cell distribution width in type 2 diabetic patients
par: Nada AM
Publié: (2015)

Fixed combination of repaglinide and metformin in the management of type 2 diabetes
par: Robert Moses
Publié: (2009)

Minimizing the risk of hypoglycemia in patients with type 2 diabetes mellitus
par: Pamela Kushner
Publié: (2010)

Pleiotropic effects of rosuvastatin on microvascular function in type 2 diabetes
par: Henri K Parson, et autres
Publié: (2010)

Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes
par: Joshua J Neumiller, et autres
Publié: (2010)

Gender difference in response predictors after 1-year exenatide therapy twice daily in type 2 diabetic patients: a real world experience
par: Anichini R, et autres
Publié: (2013)

Potential glycemic overtreatment in patients ≥75 years with type 2 diabetes mellitus and renal disease: experience from the observational OREDIA study
par: Penfornis A, et autres
Publié: (2015)

Optimal management of type 2 diabetes in patients with increased risk of hypoglycemia
par: Anderson M, et autres
Publié: (2014)

Saroglitazar for the treatment of hypertriglyceridemia in patients with type 2 diabetes: current evidence
par: Sosale A, et autres
Publié: (2015)

Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes
par: Kishimoto M
Publié: (2013)

Emerging utility of once-weekly exenatide in patients with type 2 diabetes
par: Goud A, et autres
Publié: (2015)

Obesity and the development of type 2 diabetes: the effects of fatty tissue inflammation
par: Dara P Schuster
Publié: (2010)

Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus
par: Holl, et autres
Publié: (2014)

Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes
par: Jonathan K Reynolds
Publié: (2009)

Anagliptin in the treatment of type 2 diabetes: safety, efficacy, and patient acceptability
par: Nishio S, et autres
Publié: (2015)

Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulin
par: Stanley S Schwartz
Publié: (2010)